[1]王 成,王晓玲,汪旻琦,等.女贞莲桂白芍汤联合常规辅助化疗治疗三阴性乳腺癌术后疗效研究[J].陕西中医,2023,(12):1735-1739.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.015]
　WANG Cheng,WANG Xiaoling,WANG Minqi,et al.Effects of Nvzhen Liangui Baishao decoction combined with routine adjuvant chemotherapy in the treatment of patients with triple negative breast cancer after surgery[J].,2023,(12):1735-1739.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.015]
点击复制

女贞莲桂白芍汤联合常规辅助化疗治疗三阴性乳腺癌术后疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年12期
页码:
1735-1739
栏目:
临床研究
出版日期:
2023-12-05

文章信息/Info

Title:
Effects of Nvzhen Liangui Baishao decoction combined with routine adjuvant chemotherapy in the treatment of patients with triple negative breast cancer after surgery
作者:
王 成; 王晓玲; 汪旻琦; 何宁一; 洪月光
(秦皇岛市中医医院肿瘤科,河北 秦皇岛 066003)
Author(s):
WANG Cheng; WANG Xiaoling; WANG Minqi; HE Ningyi; HONG Yueguang
(Department of Oncology,Qinhuangdao Hospital of Traditional Chinese Medicine,Qinhuangdao 066003,China)
关键词:
三阴性乳腺癌;  女贞莲桂白芍汤;  化疗;  增效减毒;  免疫功能;  肿瘤标志物
Keywords:
Triple negative breast cancer;  Nvzhen Liangui Baishao decoction;  Chemotherapy;  Enhancing effectiveness and reducing toxicity;  Immune function;  Tumor marker
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7369.2023.12.015
文献标志码:
A
摘要:
目的:观察女贞莲桂白芍汤联合常规辅助化疗对三阴性乳腺癌术后患者疗效及免疫功能、血清肿瘤标志物水平的影响。方法:选取行手术治疗的78例三阴性乳腺癌患者为研究对象,采用随机数字表法分为两组。化疗组(n=39)给予常规化疗治疗,中药组(n=39)给予女贞莲桂白芍汤联合常规化疗治疗。统计两组疗效,检测两组免疫功能指标、肿瘤标志物、血管内皮生长因子(VEGF)的水平,评估两组中医症状评分的差异,记录两组不良反应。结果:中药组总有效率高于化疗组,差异有统计学意义(P<0.05)。治疗前两组免疫功能指标、肿瘤标志物、VEGF、中医症状积分水平比较,差异无统计学意义(均P>0.05)。治疗后,中药组CD3+绝对计数、CD4+绝对计数、NK细胞、CD4+/CD8+高于化疗组,CD8+绝对计数低于化疗组(均P<0.05)。中药组治疗后肿瘤标志物、血管内皮生长因子A(VEGFA)、血管内皮生长因子C(VEGFC)水平低于化疗组,差异有统计学意义(均P<0.05)。与治疗前比较,两组治疗后头晕目眩、耳鸣、五心烦热、失眠多梦、健忘、口燥咽干、颧红盗汗、腰膝酸软、胁肋胀痛等评分下降,且中药组低于化疗组(均P<0.05)。中药组胃肠道反应、骨髓抑制Ⅲ-Ⅳ级发生率低于化疗组(均P<0.05); 中药组皮疹、脱发、神经毒性、心脏毒性Ⅲ-Ⅳ级发生率与化疗组比较,差异无统计学意义(均P>0.05)。结论:女贞莲桂白芍汤联合常规辅助化疗治疗可降低三阴性乳腺癌术后患者肿瘤标志物的表达,调节免疫功能,减少不良反应。
Abstract:
Objective:To observe the effects of Nvzhen Liangui Baishao decoction combined with routine adjuvant chemotherapy on the efficacy,immune function and serum tumor markers of patients with triple negative breast cancer after surgery.Methods:78 patients with triple negative breast cancer who underwent surgical treatment were selected and divided into two groups by random number table method.Chemotherapy group(n=39)was treated with conventional chemotherapy,and Chinese medicine group(n=39)was treated with Nvzhen Liangui Baishao decoction combined with conventional chemotherapy.The therapeutic effects of the two groups were evaluated,the levels of immune function indexes,tumor markers and vascular endothelial growth factor family(VEGF)of the two groups were detected.The differences in TCM symptom scores between the two groups were evaluated.Two groups of toxic and side effects were recorded.Results:The total effective rate of decoction group was higher than that of chemotherapy group,the difference was statistically significant(P<0.05).There was no significant difference in immune function indexes,tumor markers,VEGF and TCM symptom scores between the two groups before treatment(all P>0.05).After treatment,the absolute count of CD3+,CD4+,NK cells and CD4+/CD8+ in Chinese medicine group were higher than those in chemotherapy group,and the absolute count of CD8+ was lower than those in chemotherapy group(all P<0.05).After treatment,the levels of tumor markers,VEGFA and VEGFC in TCM group were lower than those in chemotherapy group,and the differences were statistically significant(all P<0.05).Compared with before treatment,the scores of dizziness,tinnitus,five upset fever,insomnia and dreams,forgetfulness,dry mouth and throat,zygomatic red night sweat,waist and knee pain,hypochetal swelling and pain were decreased in the two groups after treatment,and the Chinese medicine group was lower than the chemotherapy group(all P<0.05).The incidence of gastrointestinal reaction and myelosuppression of grade Ⅲ to Ⅳ in Chinese medicine group was lower than that in chemotherapy group(all P<0.05).There was no significant difference in the incidence of rashes,alopecia,neurotoxicity and cardiotoxicity of grade Ⅲ to Ⅳ in Chinese medicine group compared with chemotherapy group(all P>0.05).Conclusion:Nvzhen Liangui Baishao decoction combined with routine adjuvant chemotherapy can reduce the expression of tumor markers after triple negative breast cancer surgery,regulate immune function,and reduce adverse reactions.

参考文献/References:

[1] 李秀华,唐冬梅,朱丽萍,等.三阴性乳腺癌临床病理特征与基因分型研究[J].陕西医学杂志,2021,50(8):1015-1018.
[2] 冯 霞,肖 建,刘志勇,等.表柔比星联合白蛋白紫杉醇治疗对晚期三阴性乳腺癌患者血清BRCA1及FOXA1水平的影响[J].临床和实验医学杂志,2022,21(5):508-512.
[3] 陈玮黎,薛晓红,李思雨,等.扶正祛邪方对三阴性乳腺癌术后复发转移及免疫功能的影响[J].陕西中医,2021,42(6):739-742.
[4] 田丽丽.中医辨证分型在晚期三阴性乳腺癌化疗后的临床研究[J].中国药物与临床,2021,21(3):444-446.
[5] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754.
[6] 张玉珍.中医妇科学[M].北京:中国中医药出版社,2002:132.
[7] 潘宏铭,耿宝琴.肿瘤化疗的毒副反应和防治[M].上海:上海科学技术出版社,2001:5-6.
[8] 蒋朝霞,彭卫军,许玲辉,等.RECIST标准在乳腺癌转移治疗疗效评价中的应用与WHO标准比较[J].中国癌症杂志,2008,18(2):106-109.
[9] 白 燕,李俊杰,任新瑜,等.基于监测和流行病学及最终结果数据库的双侧原发性三阴性乳腺癌临床病理特征及预后分析[J].中国医药,2022,17(3):334-339.
[10] 张佳慧,于明薇,王笑民,等.中医药改善三阴性乳腺癌术后患者生活质量临床观察[J].北京中医药大学学报,2022,45(11):1095-1102.
[11] 梅荷婷,卢雯平,卓至丽,等.从中医证型角度探讨三阴性乳腺癌转移的相关因素[J].中国医药导报,2022,19(33):104-107.
[12] 陈明明,郭 旭,熊乙霓,等.固本培元法治疗乳腺癌化疗后骨髓抑制临床研究[J].陕西中医,2022,43(8):1049-1051.
[13] 董莹莹,朱 垚,李 柳,等.国医大师周仲瑛辨治乳腺癌临证医案症-机-药规律探析[J].中国中医药信息杂志,2022,29(12):16-22.
[14] 刘美红,邹峥嵘.女贞子化学成分、药理作用及药动学研究进展[J].热带亚热带植物学报,2022,30(3):446-460.
[15] 黄少杰,陈海霞,牟 菲,等.二至丸化学成分及药理作用研究进展[J].中华中医药杂志,2021,36(11):6617-6619.
[16] 杨慧芬,毛娟娟.二至丸合桂枝汤对三阴性乳腺癌细胞系顺铂耐药性的调控作用[J].中国医药导报,2021,18(25):19-25.
[17] 尚昱志,李陈玲,韦露秋,等.基于网络药理学的大枣补血机制初探[J].中国食物与营养,2021,27(5):58-62.
[18] 高 宇,孙建荣,邓 超,等.基于网络药理学及分子对接研究探索生姜泻心汤治疗化疗相关腹泻的作用机制[J].海南医学院学报,2022,28(13):1010-1020.
[19] Fleming CA,Jordan P,O'leary DP,et al.Perioperative cell-free DNA trends predict recurrence of non-metastatic colorectal cancer significantly earlier than CEA trends over the first 2 years post-operatively in stageⅡand stage Ⅲ colon cancer[J].International Journal of Colorectal Disease,2022,37(5):1119-1126.
[20] 康 锋,代凤霞.乳腺癌组织中孕激素受体、人表皮生长因子受体-2检测联合动态增强磁共振成像对乳腺癌术后复发时间的预测价值[J].陕西医学杂志,2022,51(11):1427-1440,1452.
[21] Sahin S,Caglayan MO,Uestuendag Z.Recent advances in aptamer-based sensors for breast cancer diagnosis:Special cases for nanomaterial-based VEGF,HER2,and MUC1 aptasensors[J].Mikrochimica Acta,2020,187(10):549.
[22] 钟恋君,王进京,郑 洪.三阴型乳腺癌间质肿瘤浸润淋巴细胞CD4、CD8、Foxp3和PD-L1表达的临床病理意义[J].临床与实验病理学杂志,2022,38(3):278-283,288.

相似文献/References:

[1]刘 丹,胥 旸,邢晓静.鸦胆子苦醇对三阴性乳腺癌细胞凋亡的影响[J].陕西中医,2021,(4):419.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.003]
　LIU Dan,XU Yang,XING XiaoJing.Effects of BRU on apoptosis of triple negative breast cancer cells[J].,2021,(12):419.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.003]
[2]陈玮黎,薛晓红,李思雨,等.扶正祛邪方对三阴性乳腺癌术后复发转移及免疫功能的影响[J].陕西中医,2021,(6):739.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.015]
[3]骆小珊,谢 甦,朱曼荆,等.薯蓣丸联合紫杉醇抑制三阴性乳腺癌细胞MDA-MB-231上皮间质转化作用和机制研究[J].陕西中医,2023,(9):1163.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.001]
　LUO Xiaoshan,XIE Su,ZHU Manjing,et al.Effect and mechanism of Dioscorea pills combined with paclitaxel on epithelial-mesenchymal transition in triple-negative breast cancer MDA-MB-231 cells[J].,2023,(12):1163.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.001]

备注/Memo

备注/Memo:
基金项目:河北省中医药管理局科研课题(2020369)
更新日期/Last Update: 2023-12-08